Develops cellular therapies for age-related diseases.
Jun 2026Revenue $18.7M/yrExpenses $68.0M/yr
No trendCash runway ≈ 1 month from Jun 2026
Figures by year
When will Celularity be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $18.7M and expenses $68.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $26.6M | $87.9M | −$61.3M |
| Dec 2024 | $54.2M | $92.6M | −$38.4M |
| Dec 2023 | $22.8M | $215M | −$192M |
| Dec 2022 | $18.0M | $43.6M | −$25.6M |
| Dec 2021 | $21.3M | $130M | −$109M |
| Dec 2020 | $14.3M | $166M | −$152M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.